Swarup Kumar Tarai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Swarup Kumar Tarai has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Saikat Mandal
Department of Biochemistry and Molecular Biology, Michigan State University
5 shared publications - Sankar Chandra Moi
Department of Chemistry, National Institute of Technology Durgapur, M. G. Avenue, Durgapur 713209, West Bengal, India
5 shared publications - Angana Pan
Department of Chemistry National Institute of Technology Durgapur Durgapur India
4 shared publications - Rituparna Bhaduri
Department of Chemistry National Institute of Technology Durgapur Durgapur India
4 shared publications - Subhajit Mukherjee
Department of Chemistry, National Institute of Technology, Durgapur-713209, India
2 shared publications - Venkata Pera Reddy B
Natl Inst Technol, Dept Chem, Durgapur 713209, WB, India
2 shared publications
Latest Publications
- 9 June 2023
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 37 (8)
Biophysical study on DNA and BSA binding activity of Cu(II) complex: Synthesis, molecular docking, cytotoxic activity, and theoretical approach
The bidentate (N, O) donor Schiff base, methyl‐4‐(2‐hydroxybenzylidene‐amino) benzoate (HL), was synthesized for the synthesis of CuL2 complex. Their structures were characterized by single crystal X‐ray diffraction and spectroscopic methods. The important structural features of ligand HL are (space group: Pca21; a = 6.1434(7) Å; b = 7.1021(7) Å; c = 28.963(3) Å; α = 90.00°; β = 90.00°, and γ = 90.00°) and of CuL2 are (space group: P21/n; a = 15.763(7) Å; b = 8.1921(5) Å, and c = 20.1955(8) Å; α = 90.00°; β = 96.547(4)°, and γ = 90.00°). The DFT/TD‐DFT studies were performed to evaluate the structure optimization, MEP plot, and electronic spectroscopy data as well as the HOMO‐LUMO energy and also other electronic descriptor properties. The DNA and BSA binding property of both the ligand and complex were studied employing a variety of spectroscopic methods, viscosity experiments, and gel electrophoresis technique. Their biophysical study including 3D fluorescence, FRET calculation, and anisotropy measurements with BSA were studied by spectrofluorometric methods. The molecular docking simulation of the ligand HL and CuL2 was executed with DNA and BSA to observe their different weak and strong binding interactions and to compare their binding aptitude with biomolecules and experimental results. The software “PASS” for drug likeness prediction and “ADMET” for bioactivity were implemented to get an idea about the antineoplastic and bioactivity aspects of HL and CuL2 complex. The anticancer property of the Cu(II) complex was measured by MTT assay against human breast carcinomas (MCF‐7) cancer cell line and as well as normal human embryonic kidney cells (HEK293) and is less toxic and comparable anticancer activity compared to cisplatin and oxaliplatin. The annexin V‐FITC, propidium iodide assay by flow cytometric method, and reactive oxygen species (ROS) production assay by DCFDA were assessed in presence of the HL and CuL2 for their cell death mechanism proceed via either apoptosis or necrosis.
- 9 June 2023
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 37 (8)
Biophysical study on DNA and BSA binding activity of Cu(II) complex: Synthesis, molecular docking, cytotoxic activity, and theoretical approach
The bidentate (N, O) donor Schiff base, methyl‐4‐(2‐hydroxybenzylidene‐amino) benzoate (HL), was synthesized for the synthesis of CuL2 complex. Their structures were characterized by single crystal X‐ray diffraction and spectroscopic methods. The important structural features of ligand HL are (space group: Pca21; a = 6.1434(7) Å; b = 7.1021(7) Å; c = 28.963(3) Å; α = 90.00°; β = 90.00°, and γ = 90.00°) and of CuL2 are (space group: P21/n; a = 15.763(7) Å; b = 8.1921(5) Å, and c = 20.1955(8) Å; α = 90.00°; β = 96.547(4)°, and γ = 90.00°). The DFT/TD‐DFT studies were performed to evaluate the structure optimization, MEP plot, and electronic spectroscopy data as well as the HOMO‐LUMO energy and also other electronic descriptor properties. The DNA and BSA binding property of both the ligand and complex were studied employing a variety of spectroscopic methods, viscosity experiments, and gel electrophoresis technique. Their biophysical study including 3D fluorescence, FRET calculation, and anisotropy measurements with BSA were studied by spectrofluorometric methods. The molecular docking simulation of the ligand HL and CuL2 was executed with DNA and BSA to observe their different weak and strong binding interactions and to compare their binding aptitude with biomolecules and experimental results. The software “PASS” for drug likeness prediction and “ADMET” for bioactivity were implemented to get an idea about the antineoplastic and bioactivity aspects of HL and CuL2 complex. The anticancer property of the Cu(II) complex was measured by MTT assay against human breast carcinomas (MCF‐7) cancer cell line and as well as normal human embryonic kidney cells (HEK293) and is less toxic and comparable anticancer activity compared to cisplatin and oxaliplatin. The annexin V‐FITC, propidium iodide assay by flow cytometric method, and reactive oxygen species (ROS) production assay by DCFDA were assessed in presence of the HL and CuL2 for their cell death mechanism proceed via either apoptosis or necrosis.
- 25 August 2022
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 36 (11)
Anticancer property and normal cell toxicity profile of pyrrolidine‐based platinum (II) complexes: Their DNA, BSA interaction, and molecular docking
The bioactivity and cytotoxic property of cis‐[Pt (AEP)Cl2] (C‐1); [Pt (AEP)(OH2)2](NO3)2 (C‐2); [Pt (AEP)(GSH) (C‐3)]; and [Pt (AEP)(DL‐meth)]2+(C‐4) (where AEP = 1‐[2‐Aminoethyl] pyrrolidine; GSH = Glutathione; DL‐meth = DL‐methionine) were extensively investigated to find out the more active and less toxic anticancer lead molecules. Spectroscopically characterized Pt (II) complexes (C‐1 to C‐4) were under investigation for their anticancer activity and bio‐molecular interaction with DNA and BSA. The binding property of the complexes toward DNA and BSA were evaluated by UV–Vis, fluorescence spectroscopy, gel electrophoresis, cyclic voltammetry (CV), circular dichroism (CD), and viscometric methods for their pharmacokinetic and pharmacodynamics importance. The BSA binding activity as well as their “Drug reservoir” property of Pt (II) complexes were highlighted for their biological significance. Furthermore, to assess the manner of interaction and also binding strength of the complexes with DNA and BSA molecule, a theoretical approach by molecular docking was performed, utilizing the optimized structure of the complexes. Structural optimization has been performed with density functional theory (DFT) correlation functional (B3LYP) at 6‐31G + (d, p) and LANL2DZ basis set was used for C, N, H, O, S, and metal, respectively. In vitro anticancer activity and level of ROS generation in presence of each complex were explored on A549 cancer cell as well as normal human cell lines HEK293, and their potential cytotoxic property was observed as compared to well‐known recognized anticancer cisplatin.
- 25 August 2022
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 36 (11)
Anticancer property and normal cell toxicity profile of pyrrolidine‐based platinum (II) complexes: Their DNA, BSA interaction, and molecular docking
The bioactivity and cytotoxic property of cis‐[Pt (AEP)Cl2] (C‐1); [Pt (AEP)(OH2)2](NO3)2 (C‐2); [Pt (AEP)(GSH) (C‐3)]; and [Pt (AEP)(DL‐meth)]2+(C‐4) (where AEP = 1‐[2‐Aminoethyl] pyrrolidine; GSH = Glutathione; DL‐meth = DL‐methionine) were extensively investigated to find out the more active and less toxic anticancer lead molecules. Spectroscopically characterized Pt (II) complexes (C‐1 to C‐4) were under investigation for their anticancer activity and bio‐molecular interaction with DNA and BSA. The binding property of the complexes toward DNA and BSA were evaluated by UV–Vis, fluorescence spectroscopy, gel electrophoresis, cyclic voltammetry (CV), circular dichroism (CD), and viscometric methods for their pharmacokinetic and pharmacodynamics importance. The BSA binding activity as well as their “Drug reservoir” property of Pt (II) complexes were highlighted for their biological significance. Furthermore, to assess the manner of interaction and also binding strength of the complexes with DNA and BSA molecule, a theoretical approach by molecular docking was performed, utilizing the optimized structure of the complexes. Structural optimization has been performed with density functional theory (DFT) correlation functional (B3LYP) at 6‐31G + (d, p) and LANL2DZ basis set was used for C, N, H, O, S, and metal, respectively. In vitro anticancer activity and level of ROS generation in presence of each complex were explored on A549 cancer cell as well as normal human cell lines HEK293, and their potential cytotoxic property was observed as compared to well‐known recognized anticancer cisplatin.
- 7 November 2021
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 36 (2) , e6506
Anticancer activity and biomolecular interaction of Pt(II) complexes: Their synthesis, characterisation and DFT study
Cis‐[Pt (TEEDA)Cl2]; 1 (where TEEDA = N,N,N′‐triethylethylenediamine) was synthesised, and its SCXRD structure was determined. Complex 1 crystallises in the monoclinic space group I2/a; (z = 8) and unit cell parameters are a = 15.1919(4) Å; b = 9.6049(3) Å; c = 16.7825 Å; α = 90.00°; β = 94.784(3)° and γ = 90.00°. Complex 1 was hydrolysed to diaqua species cis‐[Pt (TEEDA)(H2O)2]2+; 2 L‐cysteine (L‐cys) and N‐acetyl‐L‐cysteine (N‐ac‐L‐cys) chelated complex cis‐[Pt (TEEDA)(L‐cys)]+ 3 and cis‐[Pt (TEEDA)(N‐ac‐L‐cys)] 4 were synthesised and characterised by spectroscopic methods. Kinetic study of substitution reactions of Complex 2 to Complexes 3 and 4 have been explored with the thiols L‐cys and N‐ac‐L‐cys, respectively. The theoretical study with density functional theory (DFT) has been considered to optimise the structures of Complexes 1–4 for HOMO–LUMO energy calculation, TD‐DFT simulation and natural bond orbital (NBO) analysis to support structural characterisation of the complexes. Various electronic properties, known as DFT‐based descriptors, have been calculated from frontier molecular orbital energies to correlate with the adduct formation aptitude of the complexes with DNA and BSA. The binding aptitude and binding mode of the complexes with DNA and BSA have been performed by UV‐Vis and spectrofluorometric titration methods. To observe the interaction of the complexes with CT‐DNA, gel electrophoresis experiment has been carried out. A molecular docking study of the complexes was performed with DNA and BSA. The anticancer activity and ROS generation of the complexes were investigated on different cancer cell lines and fibroblast cells with DCF‐DA using FITC filter.
- 7 November 2021
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 36 (2) , e6506
Anticancer activity and biomolecular interaction of Pt(II) complexes: Their synthesis, characterisation and DFT study
Cis‐[Pt (TEEDA)Cl2]; 1 (where TEEDA = N,N,N′‐triethylethylenediamine) was synthesised, and its SCXRD structure was determined. Complex 1 crystallises in the monoclinic space group I2/a; (z = 8) and unit cell parameters are a = 15.1919(4) Å; b = 9.6049(3) Å; c = 16.7825 Å; α = 90.00°; β = 94.784(3)° and γ = 90.00°. Complex 1 was hydrolysed to diaqua species cis‐[Pt (TEEDA)(H2O)2]2+; 2 L‐cysteine (L‐cys) and N‐acetyl‐L‐cysteine (N‐ac‐L‐cys) chelated complex cis‐[Pt (TEEDA)(L‐cys)]+ 3 and cis‐[Pt (TEEDA)(N‐ac‐L‐cys)] 4 were synthesised and characterised by spectroscopic methods. Kinetic study of substitution reactions of Complex 2 to Complexes 3 and 4 have been explored with the thiols L‐cys and N‐ac‐L‐cys, respectively. The theoretical study with density functional theory (DFT) has been considered to optimise the structures of Complexes 1–4 for HOMO–LUMO energy calculation, TD‐DFT simulation and natural bond orbital (NBO) analysis to support structural characterisation of the complexes. Various electronic properties, known as DFT‐based descriptors, have been calculated from frontier molecular orbital energies to correlate with the adduct formation aptitude of the complexes with DNA and BSA. The binding aptitude and binding mode of the complexes with DNA and BSA have been performed by UV‐Vis and spectrofluorometric titration methods. To observe the interaction of the complexes with CT‐DNA, gel electrophoresis experiment has been carried out. A molecular docking study of the complexes was performed with DNA and BSA. The anticancer activity and ROS generation of the complexes were investigated on different cancer cell lines and fibroblast cells with DCF‐DA using FITC filter.
- 17 December 2020
- Published by Elsevier in Inorganica Chimica Acta
- Vol. 517, 120202
Drug reservoir mechanism of Pt(II)-sulfur chelates based on pharmacokinetics of Pt(II) complex with thiols & thio-ethers: An experimental and theoretical approach
- 17 December 2020
- Published by Elsevier in Inorganica Chimica Acta
- Vol. 517, 120202
Drug reservoir mechanism of Pt(II)-sulfur chelates based on pharmacokinetics of Pt(II) complex with thiols & thio-ethers: An experimental and theoretical approach